6 Month Injectable Contraceptive

• User: Female
• Hormonal: Hormonal
• Delivery type:
  • Injectable
• Intended Duration:
  • Short-Acting
• Development Stage: Phase III
• Developer(s)/researcher(s): FHI 360
• Contact: Sarah Cordes - Clinical Research Operations Manager, FHI 360

Details

• API: Medroxyprogesterone Acetate
• Target: Progesterone Receptor
• Mechanism of Action:
  • Ovulation Inhibition
  • Cervical Mucus Changes
  • Endometrial Changes
• Regimen: 1 Injection/6 Months
• MPT: Not Potential MPT
• Promising Attributes: 6 month interval between doses reduces user and health system burden and improves adherence and satisfaction

Product Status